Tervetuloa

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Understanding type 2 inflammation^* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.¹

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262